Effective nasal influenza vaccine delivery using chitosan
Effective nasal influenza vaccine delivery using chitosan
复制标题
DOI：
10.1016/j.vaccine.2005.04.021
复制
发表时间：
2005-08-15
期刊：
影响因子：
5.5
通讯作者：
Jennings, R
中科院分区：
文献类型：
--
作者：
Read, RC;Naylor, SC;Jennings, R
鼻流感疫苗接种可能被证明是肠外注射的良好替代方案，因为它可以增强粘膜免疫反应并且易于接种疫苗。这项研究调查了壳聚糖（一种生物粘附聚合物）作为灭活亚单位流感疫苗鼻腔给药系统的用途。受试者经鼻接受 15 或 7.5 μg 含壳聚糖的标准灭活三价流感疫苗，或肌内注射 15 μg 相同疫苗。之前测量了所有三种疫苗成分的血清血凝抑制（HI）滴度。以及给药后长达 14 周的时间点。鼻内接种鼻壳聚糖流感疫苗后的血清 HI 滴度符合专利药品委员会制定的标准，包括所用疫苗接种计划中三种抗原中至少一种的血清保护率、血清转化率和 HI 滴度平均增加倍数。这些数据表明，用壳聚糖加三价灭活流感疫苗进行鼻腔免疫是一种潜在有效且易于施用的疫苗接种形式。 (c) 2005 Elsevier Ltd. 保留所有权利。
Nasal influenza vaccination may prove to be a good alternative to parenteral injection because of the enhancement of the mucosal immune response and the ease of vaccine administration. This study investigated the use of chitosan, a bioadhesive polymer, as a nasal delivery system with inactivated, subunit influenza vaccine. Subjects received nasally 15 or 7.5 mu g of the standard inactivated trivalent influenza vaccine with chitosan or 15 mu g of the same vaccine intramuscularly. Serum haemagglutination inhibition (HI) titres for all three vaccine components were measured prior to. and at time points up to 14 weeks after dosing. Serum HI titres following intranasal vaccination with the nasal chitosan-influenza vaccine met the criteria set by the Committee for Proprietary Medicinal Products in terms of seroprotection rate, seroconversion rate and mean fold increase of HI titre for at least one of the three antigens in the vaccination schedules used. These data show that nasal immunisation with chitosan plus trivalent inactivated influenza is a potentially effective, easily-administered form of vaccination. (c) 2005 Elsevier Ltd. All rights reserved.